Propanc Biopharma (OTCQB: PPCB) is taking major steps to position itself among companies that have made the transition into human trials and deeper into innovation. Propanc’s latest meetings with regulators and research organizations, industry groups, and investors put it on a path to outperform other microcap cancer technology stocks.
The company has established proof of concept in animals, completed a full preclinical development program including establishing a safe starting dose for humans, and its publications are wide ranging. Topics include disruption of cell-to-cell contact which is pivotal for the ability and of cancer cells to promote further cancer-causing activity in neighboring cells. It is precisely this dynamic that Propanc’s enzyme-based PRP technology targets, allowing it to short-circuit cancer’s ability to spread.
Propanc has rapidly expanded its intellectual property portfolio, with holdings in four patent families. The company has 65 patents, with 48 in force and 27 pending around the world. published several peer reviewed scientific publications, completed process development and ready for scale-up manufacturing of drug product for human trials, and CEO James Nathanielsz presented at the 2019 BIO CEO & Investor Conference on February 12. The company’s publication and scientific strategy includes an abstract submitted to ASCO the American Society of Clinical Oncology which is the leading cancer conference in United States and one of the most prominent in the world. At BIO, CEO James Nathanielsz met with investors following several financing reads in order to provide financial support for clinical trials as Propanc looks to complete manufacturing runs of drug production.
Propanc has conducted several meetings with regulators and achieved orphan drug designation for pancreatic cancer, allowing for 7 years of market exclusivity in the US. The American Cancer Society estimates that in 2019 about 56,770 people (29,940 men and 26,830 women) will be diagnosed with pancreatic cancer. About 45,750 people (23,800 men and 21,950 women) will die of the disease. It is an especially deadly form of cancer, accounting for 3% of all cancer cases but 7% of all cancer deaths nationally.
Clinical Trial Strategy: Australia First
Propanc is wisely focused on its regulatory approach. The company has continued in consultation with its expert scientific advisory board and is building on scale-up manufacturing progress and movement into clinical trials to take the most efficient path toward regulatory approval by starting in Australia, which allows easy access to the rest of the world.
Australian trials are up to top global standards, and the country is now drawing US-based companies because of the high-quality infrastructure, efficiency of the regulatory process, and financial incentives to conducting those trials in the US. In terms of efficiency, Australia offers a lot. There, rather than starting top-down and dealing with the major national regulating bodies, a company can gain ethics approval from the trial site in order to begin with clinical studies.
Propanc has solid clinical logic behind selecting certain trial sites in Australia as well, since the country’s top cancer hospital the state-of-the-art Peter MacCallum Cancer Center (PeterMac) is in its back yard in Melbourne, and other appealing, high-quality phase I and II trial sites have been identified in the country. PeterMac would give Propanc high-quality patient access and GCP (good clinical practice) facilities to bridge between its GLP (good laboratory practice) proof-of-concept sutdies and GMP (good manufacturing practice) large-scale production design.
From a budgetary standpoint, Australia encourages clinical trials in the country with a 43% R&D tax incentive benefit, including overseas expenditures if they amount to no more than 50% of overall project costs. This amounts to non-dilutive financing when the cash comes back from Canberra, helping Propanc pursue further R&D. Propanc is taking a mature and measured approach to help it outperform microcap companies looking to take an innovative approach to fighting cancer.
Pharmacyte Biotech Inc. (OTCQB: PMCB) uses its Cell-in-a-Box® technology to deliver lower doses of chemotherapy drugs via encapsulation to treat pancreatic cancer, but it hasn’t managed to break above 80 cents per share since mid-2018 despite completing a final pre-production run in September of that year. Marker Therapeutics Inc. (NASDAQ: MRKR) is one microcap cancer stock that has risen and stayed elevated following positive pipeline updates early in January 2019.
The Wealthy Venture Capitalist is a series of industry-focused investment articles focused on showing everyday Investors new opportunities in rapidly growing, little-known stocks in three of the markets hottest sectors— healthcare, tech and consumer products.
Sign up for Alerts
Text message alerts: http://clk2.it/k7oF5z
Email alerts: http://wealthyventurecapitalist.com/newsletter/
Follow The Wealthy Venture Capitalist on Social Media
This report/release/profile is a commercial advertisement and is for general information and entertainment purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Venture Capitalist and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Venture Capitalist encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Venture Capitalist makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be ”forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as ”projects”, ”foresee”, ”expects”, ”will”, ”anticipates”, ”estimates”, ”believes”, ”understands”, or that by statements indicating certain actions ”may”, ”could”, or ”might” occur. Understand there is no guarantee past performance will be indicative of future results.
The Wealthy Venture Capitalist’s parent company has been, and will be, compensated an average of $6,500 per month over a 1-year contract by Propanc Health Group. We have also been compensated 8 million restricted common shares of Propanc Health Group by the Company, and will sell these shares into the market as soon as the 144 hold period has lapsed.
Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.